In recent years, research has indicated that dasatinib may be effective in treating patients with chronic myeloid leukaemia. But the treatment has many risks, including the possibility of a potentially deadly reaction to the drug. Because of this, it is important to know the dosage and the side effects of the drug before starting treatment. In this article, we will review the safety of dasatinib and its dosage for chronic myeloid leukaemia.
What is Dasatinib
Dasatinib has been approved by the FDA for the treatment of chronic myeloid leukomaemia (CML). This drug is taken once or twice a day, and may cause anemia, low white blood cells, and low platelets. It may also cause fluid buildup in the lung, a condition called pulmonary hypertension. It can lead to a rash, and doctors should closely monitor patients’ blood counts. If they fall too low, the drug may be stopped.
In this phase of the trial, patients with CML-CP were treated with dasatinib. The median time to major HR was 64 days and MCyR was 58 days, ranging from 57 to 85 days. Most patients achieved a sustained HR, and median relapse-free survival was 93 days. There were 18 patients who lost a response to dasatinib. However, the duration of these events was too short to estimate the time to relapse.
How does work Dasatinib
Dasatinib is approved by the FDA as an initial therapy for the treatment of chronic myeloid leukomaemia (CML). It is taken orally once a day or twice a day depending on the dosage. The side effects of dasatinib include anemia, low white blood cell counts, and a risk of fluid in the lung or pulmonary hypertension. Doctors regularly monitor blood counts and may stop the treatment if the level drops too low.
Unlike imatinib, dasatinib has fewer interactions with the SRC family of kinases and the activation loop of BCR-ABL. As a result, dasatinib has low activity against certain BCR-ABL-related mutations, such as T315I and V299L. It also shows low activity against G250E and Q252H.
Dosage instruction
One important aspect of dasatinib treatment is the dose. During the initial stages, the dose should be low to avoid the development of toxicity. The drug causes thrombocytopenia in human subjects and platelet dysfunction in vitro. In addition to thrombocytopenia, dasatinib can also lead to pleural effusions and hemorrhage. Although these side effects are rare, they should be avoided.
The dosage range for dasatinib is between 15 and 240 mg per day. Although its AUC is dose proportional, its elimination is linear. However, a higher dose than this can result in serious side effects. If your doctor deems it necessary, you can try lower doses. This may help to bring side effects under control and resume treatment at a lower dosage.
is it effective for chronic myeloid leukaemia
A phase III trial of dasatinib, which is used to treat patients with chronic myeloid leukaemia (CML), found that it is an effective treatment for this type of cancer. The drug was shown to improve the PFS and OS of patients by 3 months. It also reduced transformation rates. Those who have this disease should consider dasatinib as their first line of treatment.
Patients taking dasatinib for chronic myeloid leukaemia had lower rates of pleural effusion in the once-daily arm compared to the twice-daily arm. They also had lower rates of fatigue, diarrhea, and headaches, and experienced fewer side effects, including lung edema and pleural effusion. The treatment was well tolerated in both arms of the study.
Preacutions and warnings
Although dasatinib is effective in the treatment of chronic myeloid leukaemia, it is not without its side effects. There are some precautions that should be considered before starting treatment with this drug. Some patients have experienced side effects such as low blood counts, infections, and bleeding. However, most patients can manage these side effects without stopping the treatment.
Sprycel, the leukemia drug approved by the FDA, has been linked to an increased risk of pulmonary arterial hypertension (PAH), a rare but serious condition that occurs in the lungs. The FDA has updated the label with information about this complication. The drug is prescribed to patients with Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia.
